These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 16777893)
1. Life without COX 2 inhibitors: risks and benefits are determined by dose and potency. Sánchez-Delgado EJ BMJ; 2006 Jun; 332(7555):1451-2. PubMed ID: 16777893 [No Abstract] [Full Text] [Related]
2. [Are COX-2 inhibitors a risk factor for cardiovascular disease?]. John S; Schmieder RE Dtsch Med Wochenschr; 2002 Jan; 127(4):156-9. PubMed ID: 11807660 [No Abstract] [Full Text] [Related]
3. The practice implications of cardiovascular risks in NSAIDs. Hainsworth T Nurs Times; 2005 Jun 28-Jul 4; 101(26):26-7. PubMed ID: 16010838 [TBL] [Abstract][Full Text] [Related]
4. [COX 2 inhibitors--a further step back]. Slørdal L; Evensen S; Spigset O Tidsskr Nor Laegeforen; 2005 Apr; 125(8):1046. PubMed ID: 15852094 [No Abstract] [Full Text] [Related]
5. [Nonsteroidal anti-inflammatory drugs and the risk of cardiovascular diseases]. Jukić A; Kaliterna DM; Radić M Reumatizam; 2010; 57(1):26-8. PubMed ID: 20941937 [TBL] [Abstract][Full Text] [Related]
7. [Coxib debate on thin ice]. Järhult B Lakartidningen; 2005 Mar 7-13; 102(10):788-9; discussion 789-90. PubMed ID: 15839175 [No Abstract] [Full Text] [Related]
8. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease. Ray WA; MacDonald TM; Solomon DH; Graham DJ; Avorn J Pharmacoepidemiol Drug Saf; 2003; 12(1):67-70. PubMed ID: 12616850 [No Abstract] [Full Text] [Related]
9. Does celecoxib use increase the risk of cardiovascular events? Oviedo JA; Schroy PC Gastroenterology; 2005 Oct; 129(4):1348-50. PubMed ID: 16230088 [No Abstract] [Full Text] [Related]
10. Does the pro-hypertensive effect of cyclooxygenase-2 inhibitors account for the increased risk in cardiovascular disease? Messerli FH; Sichrovsky T Am J Cardiol; 2005 Sep; 96(6):872-3. PubMed ID: 16169380 [No Abstract] [Full Text] [Related]
11. [A step back or training pain?]. Raeder J Tidsskr Nor Laegeforen; 2005 Aug; 125(15):2050-1. PubMed ID: 16100553 [No Abstract] [Full Text] [Related]
12. Cyclooxygenase-2 inhibitors and cardiovascular risk. Smith ER Can J Cardiol; 2005 Mar; 21(3):307-8. PubMed ID: 15776124 [No Abstract] [Full Text] [Related]
14. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice. Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789 [TBL] [Abstract][Full Text] [Related]
15. Rescuing COX-2 inhibitors from the waste bin. Albini A; Noonan DM J Natl Cancer Inst; 2005 Jun; 97(11):859-60. PubMed ID: 15928309 [No Abstract] [Full Text] [Related]
16. Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease. Joshua FF; Oakley SP; Major GA Intern Med J; 2004 Apr; 34(4):153-61. PubMed ID: 15086694 [TBL] [Abstract][Full Text] [Related]
17. Postoperative NSAIDs and COX-2 inhibitors: cardiovascular risks and benefits. Jones SF; Power I Br J Anaesth; 2005 Sep; 95(3):281-4. PubMed ID: 16076922 [No Abstract] [Full Text] [Related]
18. Comment on Jüni P, Dieppe P. Older people should NOT be prescribed 'coxibs' in place of conventional NSAIDs. Stichtenoth DO; Frölich JC Age Ageing; 2004 Sep; 33(5):521. PubMed ID: 15315931 [No Abstract] [Full Text] [Related]
19. [Insights and views about cardiovascular safety of COX2 inhibitors]. Wallentin L Lakartidningen; 2005 Feb 28-Mar 6; 102(9):666, 668, 671. PubMed ID: 15804041 [No Abstract] [Full Text] [Related]
20. [Five turbulent years of coxibers. Where did the principle of caution go?]. Håkansson J; Rosenberg P Lakartidningen; 2005 May 2-15; 102(18-19):1432-4. PubMed ID: 15929426 [No Abstract] [Full Text] [Related] [Next] [New Search]